



August 22, 2018

✓ **BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: **Disclosure pursuant to Regulation 30 of the SEBI**
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards receipt of tentative USFDA approval for Nudovra (Estradiol Valerate Tablets, 3 mg and 1 mg and Estradiol Valerate and Dienogest Tablets, 2 mg/2 mg and 2 mg/3 mg) Tablets), to market a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Natazia® Tablets.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
[Signature]

[Signature]
[Name]
[Designation]
[Company Name]

For & on behalf of

[Signature]
[Name]
[Designation]
[Company Name]

www.lupin.com

Press Release



LUPIN

BSF 500257

NSF LUPIN

REUTERS LUPIN

Press Release



LUPIN

For further information or queries, please contact –

Pooja Thakran

VP – Corporate Communication